Respuesta limitada de los estrógenos en la mujer transexual (página 2)

14. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics. 1997;45:607–617.

15. Castelo-Branco C, Guerra A, Blümel JE, et al. Piel y Menopausia: efectos de la edad, estado hormonal y tratamientos. Rev Chil Obstet Ginecol 2000; 65: 143-51.

16. De Leo V, Lanzetta D, D"Antona D, et al. Transdermal estrogen replacement therapy in normal perimenopausal women: effects on pituitary-ovarian function. Gynecol Endocrinol 1996; 10: 49-53.

17. Dechering K, Boersma C, Mosselman S. Estrogen receptors alpha and beta: two receptors of a kind? Curr Med Chem. 2000;7:561–576.

18. Delmas PD. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in post-menopausal women. N Engl J Med 1997; 337:1641-1647.

19. Dietel M, Lewis MA, Shapiro S. Hormone repla-cement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiologi-cal studies on HRT: a mini-review. Hum Reprod 2005 Aug; 20(8): 2052-2060•

20. Dupuy AM. Lipid levels and cardiovascular risk in elderly women. CLIMATERIC 2008;11:74-83.

21. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, et al. Tamoxifen for Prevention of Breast Cancer: Report of the Na-tional Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371–1388•

22.  Gobeil F, Fortier A, Zhu T, Bossolasco M, Leduc M, Grandbois M, Heveker N, Bkaily G, Chemtob S, Barbaz D. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol. 2006;84:287–297.

23. Govind AP, Thampan RV. Membrane associated estrogen receptors and related proteins: localization at the plasma membrane and the endoplasmic reticulum. Mol Cell Biochem. 2003;253:233–240.

24. Gray RH. Biological and social interactions in determination of late fertility. J Biosoc Sci 1979; suppl 6: 97-115.

25. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986;231:1150–1154.

26. Greene JG. Constructing a standard climacteric scale. Maturitas 1998; 29: 25-31.

27. Gustafsson JA. What pharmacologists can learn from recent advances in estrogen signalling. Trends Pharmacol Sci. 2003;24:479–485.

28. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001;276:36869–36872.]

29. Health plan for the adult woman. International Menopause Society.Taylor & Francis 2005. pg 41-42.

30. Hewitt SC, Korach KS. Oestrogen receptor knockout mice: roles for oestrogen receptors alpha and beta in reproductive tissues. Reproduction. 2003;125:143–149.

31. Ho KJ, Liao JK Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol. 2002;22:1952–1961.

32. http://www.medicamentosplm.com/productos/primogyn_grageas.htm. PLM 2012

33. Lobo R. Is low dose hormonal replacement efficacious and desirable? Climacteric 2001; 4:110-119. Updated practical recomendations for hormona replacement therapy in the peri and postmenopause. CLIMATERIC 2008; 11:108-123.

34. Mac Lean AB, Nicol LA, Hodgings MB, Inmuno-histoquimical of estrogen receptors in the vulva and vagina. Reprod Med. 1999:35: 1015-1016.

35. Magnes RR. Ovarian secretion and vascular funtion. En: Naftolin F, editor. Ovarian secretions and cardiovascular and neurogical funtions. Nueva York: Raven Press; 1990.p.93-125.

36. Marín F. Moduladores selectivos del receptor estrogénico: nuevas perspectivas para el tratamiento de la menopausia. Endocrinología 1997; 44:311-314.

37. Moore RA Livial: review of Clinical studies. Br J Obstet Gynaecol 1999 :106: 1-21.

38. Nakayama Y, Sakamoto H, Satoh K, Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett 2000 Dec 8; 161(1): 63-71•

39. Palacios S, Menéndez C. Alteraciones del tracto génito-urinario bajo y menopausia. En: Palacios S, editor. Climaterio y menopausia, Madrid: Grefol SA; 1992.p.105-109

40. Panay N. HRT: does the dose matter? CLIMACTERIC 2008; 11:177-178.

41. Panyakhamlerd K, Chotnopparatpattara P, Taechakraichana N, et al. Skin thickness in different menopausal status. Journal of the Medical Association of Thailand 1999;82: 352-6.

42. Picariello L, Fiorelli G, Martineti V, Tognarini I, Pam-paloni B, Tonelli F, Brandi ML. Growth response of colon cancer cell lines to selective estrogen receptor modula-tors. Anticancer Res 2003 May-Jun; 23(3B): 2419-2424

43. Qiu Y, Langman MJS and Eggo MC. Targets of 17b-oestradiol-induced apoptosis in colon cancer cells: a me-chanism for the protective effects of hormone replace-ment therapy? J Endocrinol 2004; 181: 327–337

44. Salzer H, Schneider WH, Eppel W. Contraception in preclimacteric women with special regard to oral contraceptives. Wien Med Wochenschr 1980; 130: 218-21.

45. Sarrel PM, Sarrel LJ. Orgasmic difficulties. The role of the gynecolist Clicn Obstet Gynecol. North Am. 1978;21:181-203

46. Semmens JP, W Agner G. Estrogen deprivation and vaginal funtion in postmenopausal women. JAMA. 1982;248:445-448

47. Siseles N .Información y formación para el manejo actual de la mujer en su climaterio. Editorial Ascune 2005.

48. Sitruk Ware R.New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation.CLIMACTERIC 2007; 10:358-370.

49. Speroff L. A risk-benefit analisys of elective bilateral oophorectomy effect of changes in compliance with estrogen therapy on outcome. Am J Obstet Gynecol. 1991:164-165.

50. Studd J, Smith R. Oestrogens and depresion in women. The Diplomate 1994; 1:18-23.

51. Utian W H. Rol de la hormonoterapia a largo plazo en el contexto de la medicina preventiva para la mujer postmenopáusica. En: González Campos O, Arteaga Urzúa E, Contreras Castro P, editores. Menopausia y patologías asociadas, prevención y tratamiento. Santiago de Chile: Editorial Bywaters; 1998.p.23-33

52. Utian W H. The menopause and climateric. En: Phillip E, editor. Scientific Fundation of Obstetrics and Gynecology. 4ª edición. Oxfor: Butterworth-Heineman; 1991.p.199-207.

53. Utian WH. Síntomas definitivos de la postmenopausia: incorporación del uso del índice vaginal de células parabasales. Front Horm Res. 1975;3:75-95

54. Utian Wh. The true clinical features of postmenopause and oophorectomy, and their response to oestrogen therapy. S Afr Med J. 1972; 46: 732-7.

55. Van Winter JT, Bernard ME. Oral contraceptive use during the perimenopausal years. Am Fam Physician 1998; 58: 1373-7.

56. Van-Hasften M, Donker GH, Haspel AA, Thijssen JH. Oestrogen concentrations in plasma, endometrium, miometrium and vagina of menopausal women and effect of oestriol and estradiol aplications. J Steroid Biochem. 1989;33:647-653

57. Vogel HG. Mecanical properties of rat skin with ageing. En: Balin Ak, Kligman AM, editores. Aging and the skin. Nueva York: Raven Press; 1989.p.227-275

58. Wiklunk I, Karlberg J, Mattsson Lars-Ake. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: A double-blind placebo-controlled study. Am J Obstet Gynecol. 1993;168:824-830

59. Yabur JA. Epidemiología de la menopausia en Venezuela. En: Terán Dávila J, Febres Balestrini F. editores. Medicina del climaterio y la menopausia. Caracas: Editorial Ateproca; 1999.p.1-14.